Parnassus Investments, an funding administration agency that focuses on proudly owning a concentrated portfolio of U.S. giant cap shares, launched its Parnassus Worth Fairness Fund second-quarter 2025 investor letter. The total letter is on the market for obtain right here. For the second quarter of 2025, the fund reported a web return of seven.24%, outperforming its benchmark, the Russell 1000 Worth Index, which returned 3.79% for a similar interval. The fund’s prime 5 holdings are additionally listed within the letter, exhibiting the agency’s most important funding positions heading into 2025.
One of many firms talked about within the letter is
Danaher Company
(NYSE:DHR). Danaher Company (NYSE:DHR) designs, manufactures, and markets skilled, medical, analysis, and industrial services and products in the USA, China, and internationally. Over the previous month, Danaher Company (NYSE:DHR) rose by 7.69%, and its shares misplaced -23.01% of their worth during the last 12 months. On August 12, 2025, Danaher Company (NYSE:DHR) shares closed at $205.72, with a market capitalization of $147.3 billion.
Here’s what they should say about Danaher Company (NYSE:DHR) of their investor letter:
“Danaher Company’s (NYSE:DHR) valuation is engaging, contemplating its scale benefits and deeply embedded merchandise in biopharma workflows, that are troublesome to interchange with out regulatory reapproval. Moreover, the corporate’s market dominance positions it effectively to learn from secular progress developments in biologics, genetic medication and diagnostics. Though the business faces near-term demand, coverage and tariff challenges, we imagine these components have been largely mirrored within the valuation.”
A healthcare skilled in a lab coat holding a microscope and taking a look at a slide beneath the lens.dhrdhr
Danaher Company (NYSE:DHR) ranks twenty seventh in our record of the 30 hottest shares amongst hedge funds. In accordance with our knowledge,
117 hedge fund portfolios held positions in Danaher Company (NYSE:DHR) on the finish of the primary quarter of 2025, up from
101 within the earlier quarter. DHR was capable of beat earnings expectations because it reported an EPS of $1.8, beating expectations of $1.64. Whereas we acknowledge the potential of DHR as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. When you’re searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
In one other article, we coated Danaher Company (NYSE:DHR) and Jim Cramer’s views on the corporate. As well as, please take a look at our hedge fund investor letters Q2 2025 web page for extra investor letters from hedge funds and different main buyers.
